application): This is a proposal to develop inhibitors of the lethal factor (LF) zinc protease that is responsible for the deadly effects of Anthrax. The Structural Bioinformatics group intend to use homology modeling and Monte Carlo simulations to develop structural models and consensus sequences for peptides that are known to be cleaved by the lethal factor. They will then use other computational techniques to select hydroxamates from a virtual library as potential inhibitors. Approximately 40 compounds will be prepared, and tested for their ability to inhibit LF. The significant milestone proposed for Phase I is to find an LF inhibitor with a Ki <1 uM; that would be 300 times better than the best inhibitor cited in this proposal (which is also a hydroxamate)

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI045237-01
Application #
2867465
Study Section
Special Emphasis Panel (ZRG1-SSS-Z (01))
Program Officer
Baker, Phillip J
Project Start
1999-06-01
Project End
2000-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Cengent Therapeutics, Inc.
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92127